Lycopene & Carotenoids
Tomato carotenoids that modestly raise skin's UV-burn threshold
Evidence tier
Preliminary
Research weight
Citations
19 verified / 19
Classification
Joint & Skin
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.
What is Lycopene & Carotenoids?
Lycopene & Carotenoids is a joint and skin supplement used for raises the threshold for uv erythema over weeks. NutriDex grades the human evidence as Preliminary. Lycopene and related dietary carotenoids (beta-carotene, lutein) are lipophilic antioxidants that accumulate in skin and quench singlet oxygen and free radicals from UV light. Small human trials show that sustained tomato-based lycopene (~10–16 mg/day for 10–12 weeks) modestly raises the threshold for UV erythema and lowers photodamage markers like MMP-1 and mitochondrial DNA deletions. The effect is real but small — a low-SPF equivalent — and is photoprotection 'from within' that complements but does NOT replace sunscreen. A key caveat: high-dose beta-carotene supplements increased lung-cancer incidence in smokers in the CARET and ATBC trials; whole-food carotenoids do not carry this signal.
Purported Benefits
✓Raises the threshold for UV erythema over weeks
✓Singlet-oxygen quenching defense in skin
✓Reduces UV-driven MMP-1 and mtDNA damage
✓Adjunct only — not a sunscreen substitute
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Raised UV erythema threshold (photoprotection from within)Small RCTs show a modest, low-SPF-equivalent rise in erythema threshold; a 2025 40-RCT meta-analysis found no significant photoaging/MED benefit. | Preliminary | ↑ benefit · small | 2 |
| Reduced UV-driven MMP-1 and mtDNA damageA single small RCT (n=20) showed reduced MMP-1 and mtDNA deletions; mechanistic skin marker, not a clinical outcome. | Preliminary | ↑ benefit · small | 1 |
| Lower oxidative stress (reduced MDA)GRADE meta-analysis of 34 RCTs found significant MDA reduction but no effect on lipids, BP, glucose or inflammation. | Moderate | ↑ benefit · small | 2 |
| Lower blood pressureRCT meta-analyses show ~2 mmHg SBP drop (no DBP effect overall); an umbrella review rated tomato lycopene BP benefit high-certainty, but signals vary. | Mixed | ↑ benefit · small | 3 |
| Reduced prostate cancer riskObservational only: cohorts and a meta-analysis link higher intake/blood lycopene to lower risk; RCT trial data on PSA is largely null except high-baseline subgroups. | Moderate | ↑ benefit · small | 4 |
| Beta-carotene supplements raise lung cancer risk (smokers)Meta-analysis (8 trials, 167k) shows high-dose beta-carotene raises lung cancer risk in smokers; applies to that carotenoid, not whole-food lycopene. | Strong | ⚠ risk · moderate | 1 |
Dosing & Compounds
Typical Dose
~10–16 mg lycopene/day from tomato products for ≥10–12 weeks; effects build slowly.
Active Compounds
Safety & Cautions
Dietary lycopene from foods is well tolerated; very high intake can cause harmless orange-tinged skin. The major concern is high-dose beta-carotene SUPPLEMENTS, which increased lung-cancer incidence and mortality in smokers and asbestos workers (CARET, ATBC). Smokers and former smokers should avoid high-dose beta-carotene pills. Carotenoids are NOT a sunscreen replacement. Educational only — always check with your doctor or pharmacist before combining Lycopene & Carotenoids with any medicine.
Key Studies ★ 19 studies
meta-analysis
Wang 2025 (dose-response meta-analysis)
✓ PubMed
Dose-response meta-analysis of 119 prospective cohorts (108,574 cancer cases): high dietary lycopene intake was associated with 5% lower overall cancer risk (RR 0.95) and high blood lycopene with 11% lower risk (RR 0.89), with reduced cancer mortality.
meta-analysis
Hashemi 2023 (GRADE meta-analysis)
✓ PubMed
GRADE systematic review and meta-analysis of 34 RCTs found lycopene/tomato did not significantly affect lipids, blood pressure, glucose, or inflammatory markers; lycopene significantly reduced malondialdehyde (MDA), indicating modest lower oxidative stress.
systematic review & meta-analysis
Bahmani 2025 (systematic review & meta-analysis)
✓ PubMed
Systematic review and meta-analysis (29 studies) found lower serum lycopene was associated with increased metabolic-associated fatty liver disease risk (OR 1.39, 95% CI 1.02-1.89), while higher serum lycopene was associated with reduced mortality among patients with metabolic disease (HR 0.73, 95% CI 0.57-0.94).
Meta-analysis
Yang 2025
✓ PubMed
Meta-analysis of 40 RCTs (search through Oct 2024) found lycopene, carotenoids, and hyaluronic acid produced no significant benefit on skin photoaging or minimal erythema dose (MED)/elasticity, while collagen and polyphenols did; all supplements were safe over <=24 weeks.
Systematic review
Stanescu 2025
✓ Full text
Systematic review of 176 studies (2000-March 2025) reported carotenoids mitigate UV-induced oxidative damage by scavenging ROS/RNS, attenuating inflammation, and supporting collagen biosynthesis, though outcomes were too heterogeneous for quantitative pooling.
Systematic review
Nam et al. 2026 (umbrella review)
✓ PubMed
Umbrella review of 9 systematic reviews / 5 moderate-to-high-quality meta-analyses of intervention studies. Tomato-derived lycopene significantly lowered blood pressure with GRADE high certainty, but lipid-profile effects were inconsistent (very low certainty for HDL-C). Concluded daily intake of 5-30 mg lycopene (one to two raw tomatoes) is beneficial for cardiovascular risk.
Meta-analysis
Wan et al. 2024
✓ PubMed
Meta-analysis of RCTs of antioxidant lipid supplements. Lycopene vs placebo significantly lowered systolic blood pressure by 1.95 mmHg (95% CI -3.54 to -0.36); effects most evident in participants with adverse cardiometabolic status.
Meta-analysis
Kordiak 2022 (meta-analysis)
✓ PubMed
Meta-analysis (8 trials, 167,141 participants): beta-carotene supplementation increased lung-cancer risk (RR 1.16), rising to RR 1.21 in smokers/asbestos workers.
meta-analysis
Pourmasoumi 2021 (meta-analysis of RCTs)
✓ PubMed
Meta-analysis of 6 RCTs in men with non-metastatic prostate cancer found no overall effect of lycopene on PSA (WMD -0.60 ug/L), but a significant reduction (WMD -3.74 ug/L) in the subgroup with high baseline PSA (>=6.5 ug/L).
meta-analysis of RCTs
Rezaei Kelishadi 2022 (meta-analysis of RCTs)
✓ Full text
Systematic review and meta-analysis of 10 randomized trials (688 participants) found lycopene supplementation significantly reduced systolic blood pressure by ~2.6 mmHg (no significant effect on diastolic BP overall), with larger reductions at doses >=15 mg/day, durations >=8 weeks, and in participants with baseline SBP >130 mmHg.
meta-analysis
Rowles 2017 (systematic review & meta-analysis)
✓ PubMed
Systematic review and meta-analysis (42 studies, 43,851 prostate cancer cases) found higher dietary intake and higher circulating lycopene each significantly associated with reduced prostate cancer risk, with risk decreasing ~1% per additional 2 mg/day lycopene.
RCT
Metabolic Syndrome RCT 2023
✓ PubMed
Double-blind RCT (n=80, metabolic syndrome) of encapsulated lycopene 20 mg/day for 8 weeks significantly reduced CRP (p=0.001) and pro-oxidant-antioxidant balance (p=0.004) vs placebo, with no change in liver enzymes (ALT/AST/ALP).
RCT
Rizwan 2011 (RCT)
✓ PubMed
20 women taking 55 g tomato paste (16 mg lycopene) daily for 12 weeks showed a higher erythemal threshold (p=0.03) and reduced UV-induced MMP-1 and mtDNA deletion.
RCT
Aust 2005 (RCT)
✓ PubMed
12 weeks of tomato-based products (~10 mg/day lycopene) reduced UV-induced erythema by 25–48% vs baseline, with the effect growing over time.
RCT follow-up
AREDS2 Report 28 (RCT follow-up)
✓ PubMed
In the AREDS2 randomized trial 10-year follow-up (3,883 participants), directly substituting lutein/zeaxanthin for beta-carotene lowered the risk of progression to late AMD (HR 0.85, 95% CI 0.73-0.98) and avoided beta-carotene's elevated lung-cancer risk (lutein/zeaxanthin OR 1.15 vs beta-carotene OR 1.82).
Review
Ma 2025
✓ Full text
Review of C40 carotenoids (beta-carotene, lycopene, astaxanthin, lutein, zeaxanthin) in skin photoaging found oral and topical use can alleviate photoaging via ROS scavenging and modulation of MAPK, Nrf2, and NF-kB pathways, while flagging dosage, bioavailability, and pigmentation/allergy safety limits.
Cohort
Lopez-Solis et al. 2025 (PREDIMED)
✓ PubMed
Prospective cohort of 2,970 high-cardiovascular-risk Mediterranean men (PREDIMED), 104 incident prostate cancers over 5.8 yr. Highest vs lowest quartile of lycopene intake had 54% lower prostate cancer risk (HR 0.46, 95% CI 0.23-0.95; p-trend 0.035); nonlinear protection emerging above 4.9 mg/day (HR 0.36, 0.13-0.98).
prospective cohort
Wang 2022 (NHANES cohort)
✓ PubMed
Prospective cohort of 7,683 adults with chronic kidney disease (NHANES, median ~25-year follow-up) found higher serum lycopene independently associated with lower all-cause mortality (HR 0.78, 95% CI 0.71-0.85) and cardiovascular mortality (HR 0.79, 95% CI 0.69-0.91) comparing highest vs lowest quartile.
Cohort
Gann et al. 1999 (Physicians' Health Study)
✓ PubMed
Nested case-control within the Physicians' Health Study (578 cases, 1,294 controls). Highest vs lowest quintile of plasma lycopene associated with lower prostate cancer risk; in the placebo (non-beta-carotene) arm there was a ~60% reduction in aggressive prostate cancer risk for the top vs bottom quintile - an early prospective biomarker signal specific to aggressive disease.